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Abstract
Background: Herpes simplex virus type 2 (HSV-2) is a leading cause of genital ulceration that can
predispose individuals to an increased risk of acquiring other sexually transmitted infections. There
are no approved HSV-2 vaccines and current suppressive therapies require daily compound
administration that does not prevent all recurrences. A promising experimental strategy is the use
of toll-like receptor (TLR) agonists to induce an innate immune response that provides resistance
to HSV-2 infection. Previous studies showed that anti-herpetic activity varied based on origin of the
agonists and activation of different TLR indicating that activity likely occurs through elaboration of
a specific innate immune response. To test the hypothesis, we evaluated the ability of a bacterial-
derived TLR2/6 agonist (FSL-1) to increase resistance to experimental genital HSV-2 infection.
Methods: Vaginal application of FSL-1 at selected doses and times was evaluated to identify
potential increased resistance to genital HSV-2 infection in the mouse model. The FSL-1 induced
cytokine profile was quantified using kinetically collected vaginal lavages. Additionally, cytokine
elaboration and organ weights were evaluated after single or multiple FSL-1 doses to establish a
preliminary safety profile. Human vaginal EC cultures were used to confirm the mouse model
outcomes.
Results: The results showed that vaginally-applied FSL-1 created an environment resistant to a 25-
fold higher HSV-2 challenge dose. Mechanistically, vaginal FSL-1 application led to transient
elaboration of cytokines linked to anti-herpetic innate immune responses. No gross local or
peripheral immunotoxicity was observed even after multiple dosing. FSL-1 also created an anti-
herpetic environment in cultures of human vaginal epithelial cells (EC).
Conclusion: The results showed, for the first time, that the bacterial-derived TLR2/6 agonist FSL-
1 induced significant resistance to HSV-2 infection when applied in mice or human vaginal EC
cultures. Cytokine evaluation illustrated that anti-herpetic activity correlated with induction of a
specific profile. The identified anti-herpetic profile provides an invaluable resource for the future
design of novel compounds to reduce genital HSV-2 transmission and improves understanding of
the complex innate immune response to potential pathogens elicited by the vaginal mucosa.
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Introduction
Genital herpes simplex virus type 2 (HSV-2) is one of the
most wide spread sexually transmitted infections (STI)
and prevalence varies from 16-97% based on age, culture,
ethnicity, geographic location, sex and other factors [1-3].
Following genital infection, HSV-2 establishes a life-long
latency in sacral ganglia and periodically can reactivate
resulting in the formation of genital lesions [1,4]. Con-
trolling the spread of HSV-2 is important because the gen-
ital lesions can serve as portals of entry for other STI
including human immunodeficiency virus type 1 (HIV-1)
[1,5-7]. Also important to transmission cycles, HSV-2 is
frequently shed from the genital tract in the absence of
symptoms [8]. Recent studies showed that HSV-2 is asso-
ciated with coinfections and can exacerbate the patholo-
gies produced by STI [1,5-7]. So prevention of
transmission is a laudable goal, however, there are no
Food and Drug Administration-approved vaccines for
HSV-2 [1,9]. Further, treatment of existing infections
involves daily antiviral therapy that only suppresses but
does not completely prevent all recurrences [1,10]. New
approaches are needed that can prevent or reduce the like-
lihood of transmission.
One promising experimental strategy is the use of evolu-
tionarily conserved pathogen structures termed pathogen-
associated molecular patterns (PAMP) that are recognized
by toll-like receptors (TLR) [11,12]. Each TLR alone or in
a heterodimer binds to a specific PAMP and based on the
ligand initiates a particular signaling transduction cascade
[11,12]. TLR signaling elicits cytokine production and leu-
kocyte recruitment resulting in a highly coordinated
innate immune response against genital HSV-2 infection
[11,13]. Previous work showed that viral-associated TLR
agonists vaginally-applied prior to challenge increased
resistance to HSV-2 infection in mice [14-19]. Polyinos-
inic-polycytidylic acid (PIC), a synthetic TLR3 agonist
applied 24 h prior to viral inoculation significantly
increased resistance to genital HSV-2 infection and mice
that were infected showed significantly delayed disease
signs and increased survival times [17]. Similar anti-her-
petic activity was observed following application of imiq-
uimod (IMI) or unmethylated CpG oligonucleotides
(CpG), synthetic TLR7/8 or 9 agonists, respectively [14-
16,18,19]. Interestingly, murine experiments using bacte-
rial-derived TLR agonists including peptidoglycan (PGN;
TLR2), lipopolysaccharide (LPS; TLR4) or flagellin (FLAG;
TLR5) showed no significant induction of resistance to
HSV-2 [14,15]. In a recent study, FimH derived from
Escherichia coli elicited significant resistance to genital
HSV-2 infection through TLR4 activation and IFNβ pro-
duction [20]. The varying activity observed following TLR
agonist application indicates that establishment of an
HSV-2 resistant environment likely occurs through activa-
tion of a specific innate immune response.
To test the hypothesis that HSV-2 resistance could be
engendered through elaboration of a specific cytokine
response, we selected a synthetic diacyl lipopeptide
derived from Mycoplasma salivarium, fibroblast stimulat-
ing ligand-1 (FSL-1), that is recognized by TLR2/6 het-
erodimers [21,22]. TLR2 and 6 are highly expressed by
human [13] and murine [23] vaginal and lower genital
tract epithelial cells (EC). Studies showed that HSV-2 is
recognized through TLR2-mediated binding of the glyco-
protein spikes within the viral lipid envelope [11,24]. Fur-
ther, activation of TLR2/6 by FSL-1 can create an
environment that is less susceptible to infection by other
bacteria through elaboration of a specific cytokine profile
[25]. Evaluation of the HSV-2-resistant vaginal environ-
ment in specific knockout mice or in animals treated with
TLR agonists of viral origin has identified a cytokine pro-
file that includes IL-2, IL-12(p40), IFNα, IFNβ, IFNγ and
CCR5 chemokines [15-17,19]. Additionally, recent work
with primary and immortalized human vaginal EC cul-
tures showed that FSL-1 elicited innate immune responses
similar to PIC [13], therefore we hypothesized that the
FSL-1-elaborated cytokine pattern would engender resist-
ance to HSV-2 infection in the mouse model and in
human vaginal EC.
FSL-1 was tested at several doses and application times in
the mouse model and in human vaginal EC cultures to
evaluate potential induced resistance to genital HSV-2
infection. Cytokine elaboration induced by FSL-1 was
quantified for comparison to other TLR agonists to iden-
tify an innate immune response profile associated with
anti-herpetic activity. Kinetic cytokine elaboration elicited
by a single or by multiple doses of FSL-1 was quantified
and weights of relevant organs were measured to establish
a preliminary safety profile of the induced innate immune
response for the rational design of future anti-herpetic
compounds. Additionally, the impact of FSL-1 on HSV-2
replication in human vaginal EC was established to con-
firm that potential anti-herpetic activity was not specific
to the murine vaginal environment. Collectively, the
results indicated that FSL-1 induced significant resistance
to experimental genital HSV-2 infection through elabora-
tion of a specific cytokine response profile.
Materials and methods
Cell culture and HSV-2 propagation
Immortalized human vaginal EC from three different
donors (V11I, V12I, V19I) were cultured in a 1:1 mixture
of VEC-100 (MatTek, Ashland, MA) and keratinocyte
serum-free medium (Invitrogen, Carlsbad, CA) as
described previously [13]. HSV-2 strain 186 [26], pre-
pared from infected Vero cell cultures (ATCC CCL81), was
used for all experiments. Viral stocks were titered as
described previously [18] and stored at -80°C.Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
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Mouse model of genital HSV-2 infection and dose-ranging 
paradigm
Female Swiss-Webster mice (Harlan Sprague Dawley,
Indianapolis, IN) weighing 20-25 g were housed in Asso-
ciation for Assessment and Accreditation of Laboratory
Animal Care-approved quarters and provided with unlim-
ited access to food and water. All procedures were per-
formed humanely and approved by the University of
Texas Medical Branch Institutional Animal Care and Use
Committee. Following a 7d acclimation to the facility,
mice were hormonally-conditioned by subcutaneous
delivery of 150 mg/kg of Depo-Provera (UpJohn, Kalam-
azoo, MI) 7d prior to viral inoculation as described previ-
ously [17,18].
FSL-1 was diluted in Dulbecco's Phosphate Buffered
Saline (DPBS) without calcium or magnesium (Cellgro,
Herndon, VA) to achieve a 0.1 μg/μL solution and deliv-
ered vaginally using a positive displacement pipet
(Rainin, Oakland, CA) at 2 or 6 μg/mouse prior to or fol-
lowing viral challenge as specified for each experiment.
Dosing was based on FSL-1 solubility in the DPBS vehicle
and the volumetric constraints of the murine vagina
resulting in a maximum delivery of 6 μg. DPBS vehicle
treated mice were followed in parallel to serve as controls
for all experiments. Mice were swabbed with a wet then
dry calcium alginate swab (Fisher, Pittsburgh, PA) just
prior to instilling 25 μL of HSV-2 strain 186 (104pfu/
mouse) vaginally using a positive displacement pipet. The
challenge dose, a 100 times greater than the dose required
to cause lethal outcomes in 50% of the mice (LD50)
[17,18], was selected to ensure that enough mice in the
DPBS vehicle treatment group exhibited disease signs to
allow for statistical comparisons.
FSL-1-induced resistance to HSV-2 infection was quanti-
fied using the infectious dose 50% (ID50) shift paradigm
[17]. Briefly, FSL-1 doses of 2 or 6 μg/mouse were deliv-
ered at indicated times and then groups of mice were chal-
lenged with viral inoculums of 102, 103 or 104pfu (n =
10). DPBS treated groups were employed to control for
the potential impact of the vehicle on HSV-2 infection and
were challenged with viral inoculums of 101, 102  or
103pfu/mouse (n = 10). Infected animals were identified
by plating of vaginal swabs collected 2d after viral chal-
lenge [27]. Mice were assessed daily (d1-14) for the
appearance of disease signs and followed for survival as
described previously [17,18].
Cytokine quantification
Vaginal lavages were collected at 0 and 24 h after applica-
tion of FSL-1 (6 μg) or an equivalent volume of the DPBS
vehicle (60 μL) at 6 and 48 h after treatments from a sec-
ond group of mice (n = 5 mice/treatment for each group).
Lavages were collected as described previously [17] and
collections were scheduled to prevent an artificial "wash-
out" of vaginal cytokines by only sampling an animal
once within a 24 h period. For repetitive dosing evalua-
tions, vaginal lavages were collected from FSL-1 (6 μg) or
DPBS vehicle (60 μL) treated mice at 6 h (n = 5 each;
group 1) or 24 h (n = 5 each; group 2) after a once daily
application for 5 consecutive days. Vaginal cytokines in
the recovered lavages (~100 μL) were quantified using the
BioPlex Mouse Group I cytokine kit (Bio-Rad, Hercules,
CA) or by ELISA for mouse IFNα or IFNβ (PBL, New
Brunswick, NJ). Absolute cytokine quantities (pg/mL)
were extrapolated from a standard curve run in parallel.
Quantification of FSL-1 induced HSV-2 resistance in 
cultured human vaginal epithelial cells
V11I, V12I or V19I immortalized human vaginal EC were
seeded into 96 well culture plates at 1 × 105cells/well in
100 μL of medium and incubated overnight. FSL-1 (6 μg
or 0.1 μg) or the DPBS vehicle (10 μL) were added at 24,
6 or just prior to HSV-2 inoculation (104pfu/well). At 24
h post-infection (PI) the contents of each well were col-
lected (100 μL) and 50 μL was used for plaque titration
assays to quantify viral titer [18]. DNA was extracted from
the remaining 50 μL using the Qiagen DNeasy 96 Kit
(Qiagen, Valencia, CA) and subjected to quantitative Taq-
Man PCR that targeted the HSV-2 glycoprotein B gene as
described previously [28].
Statistical analyses
Data were analyzed by specific statistical tests as indicated
in the results section using the Prism software package
v4.0 (Graph Pad, San Diego, CA).
Results
FSL-1 impacted genital HSV-2 infections in mice
FSL-1 doses were applied vaginally at selected time points
relative to viral challenge to identify doses and delivery
times that could induce significant resistance to HSV-2
infection. Initially, a single application of FSL-1 (2 μg)
delivered at 24 or 6 h (n = 10 mice/group) prior to HSV-2
inoculation (104pfu) was evaluated based on efficacy
results from experimentation with other TLR agonists
[14,17]. FSL-1, delivered at either time, significantly (p <
0.05; Student's t-test) delayed the appearance of disease
signs (disease incidence) and increased survival times
compared to DPBS vehicle treated controls (Table 1).
An additional dosing regimen of FSL-1 was evaluated by
employing a potential microbicide delivery schedule con-
sisting of application prior to or just after a sexual encoun-
ter [29]. FSL-1 (2 μg/dose) was applied vaginally 1 h prior
and 1 h after HSV-2 inoculation (104pfu) to a separate
group of mice (n = 10). Interestingly, this treatment did
not impact HSV-2 disease incidence nor alter survival
times compared to DPBS vehicle treatment and was signif-Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
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icantly (p < 0.05; Student's t-test) less effective than FSL-1
(2 μg) applied at 24 or 6 h prior to viral challenge (Table
2). In an additional study, 2 other groups of mice received
3 repetitive FSL-1 doses (2 μg/dose) at 6, 5 and 4 h prior
to HSV-2 inoculation or a single 6 μg dose 6 h prior to
viral challenge. The single FSL-1 (6 μg) dose produced sig-
nificantly (p < 0.05; Student's t-test) improved outcomes
compared to DPBS vehicle application or FSL-1 (2 μg)
applied at 1 h prior and 1 h after viral inoculation (Table
1) indicating a time dependence for FSL-1-mediated
resistance to HSV-2.
Vaginal FSL-1 application increased resistance to HSV-2 by 
25-fold
Having identified 2 effective treatment times (24 and 6 h
prior to inoculation), the ID50 shift paradigm [17] was
employed to quantify the resistance to HSV-2 challenge
afforded by FSL-1. Single doses of 2 or 6 μg per mouse
were evaluated at the 2 time points to identify the most
effective FSL-1 regimen (n = 30 mice per treatment).
Treated animals then were distributed randomly into sub-
groups (n = 10) for subsequent challenge with escalating
viral doses (102, 103, or 104pfu) (Table 2). FSL-1 (2 or 6
μg) delivered at 24 or 6 h prior to viral inoculation
resulted in similar outcomes as observed in Table 1 when
genitally challenged with 104pfu of HSV-2 confirming the
previous results. Of the tested doses and times, the lower
dose of FSL-1 (2 μg) applied 24 h prior to HSV-2 inocula-
tion produced a significant shift in the ID50 (760 pfu)
resulting in a 25-fold increase in resistance to viral infec-
tion compared to DPBS vehicle treated control animals
(ID50 = 31 pfu). For the animals that were infected, the
treatment also resulted in a 10-fold increase in survival
(LD50 = 760 pfu). FSL-1 (2 μg) delivered 6 h prior to HSV-
2 challenge increased the ID50 (260 pfu) and LD50 (660
pfu) by 10-fold compared to DPBS vehicle control (Table
2). Application of FSL-1 (6 μg) at 24 or 6 h prior to viral
inoculation produced similar increases in the ID50 and
Table 1: Vaginal application of FSL-1 significantly delayed HSV-2 disease development and increased survival times.
FSL-1 and vehicle groupsa Time to symptomsb Survival timec Survivald
(days) (days) (%)
FSL-1 2 μg 24 h prior 8.0 (6.4-9.7)e, f 9.4 (7.8-11.0)e, f 1/10 (10)
FSL-1 2 μg 6 h prior 9.0 (8.1-9.9)e, f 10.1 (8.9-11.3)e, f 0/10 (0)
FSL-1 2 μg 1 h prior, 1 h after 6.0 (5.5-6.4) 7.3 (6.8-7.7) 0/10 (0)
FSL-1 2 μg 6 h, 5 h, 4 h prior 6.4 (5.9-7.0) 9.1 (7.0-11.2) 1/9 (11)
FSL-1 6 μg 6 h prior 8.5 (6.7-9.9)e, f 10.0 (8.4-11.6)e, f 4/10 (40)
DPBS vehicle control 5.8 (5.0-6.4) 7.2 (6.9-7.6) 0/8 (0)
a Intravaginal application of FSL-1 or DPBS vehicle control at selected times prior to or after vaginal inoculation of HSV-2 (104pfu).
b Mean (95% confidence interval) for day that each mice first showed disease signs within 14d PI
c Mean (95% confidence interval) for day that each mice succumbed to disease within 14d PI.
d Number of mice that did not succumb to disease within 14d PI/total number of animals in the group (percent survival).
e p < 0.05 compared to DPBS vehicle control (ANOVA, Dunnett's Test).
f p < 0.05 compared to FSL-1 2 μg 1 h prior, 1 h after (ANOVA, Dunnett's Test).
Table 2: FSL-1 application significantly protected against genital HSV-2 challenge in mice.
HSV-2 dose FSL-1 2 μg 24 h priora FSL-1 2 μg 6 h prior DPBS vehicle control
(pfu) %Infectedb %Survivalc %Infected %Survival %Infected %Survival
1 × 101 NDd ND ND ND 30 70
1 × 102 30 70 10e 90 70 50
1 × 103 50e 50e 1 0 04 01 0 0 0
1 × 104 90 10 100 0 ND ND
ID50
f 760 (80-7000) 260 (10-6000) 31 (10-80)
LD50
g 760 (80-7000) 660 (300-1000) 68 (7-700)
a Intravaginal application of FSL-1 or DPBS vehicle control at indicated times prior to vaginal HSV-2 inoculation (n = 10 mice/treatment at each HSV-
2 dose).
b Percentage of mice with infectious virus in d2 vaginal swabs.
c Percentage of mice that survived HSV-2 vaginal challenge up to d14 PI.
d ND, not determined.
e p < 0.05 compared to vehicle control (Fisher's exact test).
f Dose of the virus required to infect 50% of the mice based on %Infected data; ID50 (95% confidence interval).
g Dose of the virus required to cause lethal outcomes in 50% of the mice based on % survival data; LD50 (95% confidence interval).Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
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LD50 compared to FSL-1 (2 μg) delivered 6 h prior to HSV-
2 challenge. We examined the cytokine profile elaborated
by FSL-1 application to better understand how a bacterial-
derived TLR agonist modulated the innate immune
response to provide resistance to genital HSV-2 challenge.
FSL-1-elicited cytokines were consistent with innate 
responses previously associated with resistance to genital 
HSV-2 infection
Previous work with other TLR agonists or cytokine knock-
out mice showed that secretion of specific cytokines corre-
lated with resistance to genital HSV-2 challenge in mice
[15-17,19]. To compare established cytokine profiles to
the one produced by FSL-1, vaginal lavage samples from
mice treated with FSL-1 or equal volumes of the DPBS
vehicle were collected at 0, 6, 24 and 48 h post-applica-
tion. Individual lavages then were analyzed to quantify
specific cytokines that were significantly increased by FSL-
1 treatment compared to DPBS vehicle. The FSL-1 profile,
evident by 6 h, included significant (p < 0.05; Student's t-
test) induction of IL-1α, IL-1β, IL-2, IL-6, IL-12(p40), IL-
12(p70), G-CSF, GM-CSF, IFNα, IFNβ, IFNγ, MIP-1α,
MIP-1β and TNF-α (Table 3). Cytokine induction profiles
produced by a single 2 or 6 μg dose were indistinguishable
(data not shown). Lavage samples collected at later time
points showed that the induced cytokines had returned to
levels similar to DPBS vehicle controls within 24 h (Figure
1). Overall, the observed cytokine profile was consistent
with the profiles elaborated by other TLR agonists that sig-
nificantly reduced genital HSV-2 infection in mice [15-
17,19].
Multiple FSL-1 doses applied vaginally did not induce 
chronic inflammation or organ enlargement
Effective anti-herpetic compounds should only tran-
siently induce cytokines even after multiple dosing cycles
[17,30]. To determine if FSL-1 caused chronic cytokine
elaboration, vaginal lavages were collected at 6 and 24 h
following daily 6 μg FSL-1 applications delivered over five
consecutive days. The 6 μg dose was selected because it
was the highest tested dose that elicited resistance to gen-
ital HSV-2 infection. Cytokine production was similar to
the single dose results (Figure 1) following the first dose
and showed significant (p < 0.05; Student's t-test) induc-
tion of the indicated cytokines 6 h after FSL-1 application
(Table 3) with a return to DPBS vehicle levels by 24 h (Fig-
ure 2). The cycle of induction and return to DPBS vehicle
levels was observed after each daily dose of FSL-1 (Figure
2). Importantly, no additive effect of repeated FSL-1 dos-
ing was observed; cytokine levels 24 h after the last dose
(120 h) were indistinguishable from DPBS vehicle treated
mice (Figure 2). As an additional preliminary evaluation
of potential chronic inflammation, the weights of genital
lymph nodes (GLN), liver and spleen (n = 5 mice/group)
were determined at indicated time points after delivery of
a single or five consecutive daily 6 μg doses of FSL-1. GLN,
liver and spleen weights from treated mice were statisti-
cally (p > 0.05; Student's t-test) indistinguishable from
DPBS vehicle treated mice (Figure 3). Together, the data
indicate that repetitive 6 μg doses of FSL-1 did not elicit
chronic cytokine elaboration or cause organ enlargement
unlike the outcomes observed following CpG application
in mice [16].
FSL-1 reduced HSV-2 replication in human vaginal EC
The ability of FSL-1 to elicit anti-herpetic activity in
human vaginal EC was quantified to confirm that the
observed reduction in genital HSV-2 infection was not
specific to the mouse model and to provide data on the
role of genital EC in the resistance process. FSL-1 at the
higher 6 μg dose or at a previously tested 0.1 μg in vitro
dose [13] was added to triplicate human vaginal EC cul-
tures 24, 6 h or just prior to HSV-2 inoculation (104pfu/
well). Virus control wells received an equal DPBS vehicle
volume at the indicated times. PCR was used to quantify
reduction in HSV-2 genome equivalents (GE) for the glyc-
oprotein B gene and showed that FSL-1 (6 μg) produced
significant (p < 0.05; Student's t-test) reductions when
delivered at 24 or 6 h prior to HSV-2 inoculation (Figure
4). A similar significant (p < 0.05; Student's t-test) reduc-
tion in viral replication was measured using the plaque
titration assay. The 0.1 μg FSL-1 dose produced reduced
HSV-2 replication at 24 or 6 h prior to viral challenge (Fig-
ure 4). Three separate EC donors were tested in parallel
and produced comparable outcomes. Similar to results
obtained in the mouse model, FSL-1 added just prior to
HSV-2 inoculation did not significantly (p > 0.05; Stu-
dent's t-test) reduce viral infection (Figure 4) confirming
that FSL-1 was not inhibiting HSV-2 directly.
Discussion
For the first time, these murine studies illustrated a syn-
thetic bacterial-derived TLR2/6 agonist, FSL-1, signifi-
cantly increased resistance to genital HSV-2 infection. The
observed increase in resistance has potential implications
for HSV-2 transmission prevention by increasing the
threshold of infection above the amount of virus shed
during a sexual encounter [31,32]. FSL-1 (2 μg) applica-
tion at 24 h prior to viral inoculation engendered the
greatest resistance to experimental HSV-2 challenge of the
tested doses (25-fold increase over the DPBS vehicle ID50)
(Table 2). Based on recent epidemiological studies, even
an anti-herpetic strategy that did not completely protect
against but induced significant resistance to infection
could substantially reduce HSV-2 transmission [33]. To
confirm that the observed activity of FSL-1 was not spe-
cific to the murine model, evaluations also were pre-
formed using a model of the human vaginal mucosa.Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
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FSL-1 also elicited significant anti-herpetic activity in
human vaginal EC. The EC of the vaginal mucosa are the
initial targets of HSV-2 [1,34] and actively participate in
the innate immune response against infection [11,13].
Additionally, human and murine vaginal EC both express
high levels of TLR2 and 6 [13,23]. A significant or trended
reduction in HSV-2 GE and pfu was observed following
application of FSL-1 24 or 6 h prior to viral challenge (Fig-
ure 4). Interestingly, no anti-herpetic activity was
observed for FSL-1 applied just prior to HSV-2 infection.
The observed temporal dependant activity is consistent
Figure 1
FSL-1 transiently induced pro-inflammatory cytokines Figure 1
FSL-1 transiently induced pro-inflammatory 
cytokines. Selected cytokines were quantified kinetically 
from murine vaginal lavages (n = 5/treatment) collected 0, 6, 
24 and 48 h after FSL-1 (6 μg; closed square) or DPBS vehicle 
(60 μL; open circle) application. The pro-inflammatory 
cytokines IL-1α, IL-6 and TNF-α were significantly increased 
(*, p < 0.05; Student's t-test) 6 h after FSL-1 application com-
pared to DPBS vehicle. By 24 h, induced cytokines had 
returned to DPBS vehicle levels. Each collection time point is 
presented as mean ± SEM of five replicates from two inde-
pendent experiments.
Table 3: Vaginal application of FSL-1 in mice induced a specific 
cytokine profile.
6 h Post FSL-1 application (pg/lavage ± SEM)
Cytokinea FSL-1 DPBS vehicle
IL-1α 1083.2 ± 143.5b 527.0 ± 65.7
IL-1β 1157.0 ± 320.2c 169.2 ± 46.3
IL-2 34.8 ± 5.2d BDL(3.9)e
IL-6 418.5 ± 94.1b 35.4 ± 8.5
IL-12(p40) 104.2 ± 10.5d 44.9 ± 3.8
IL-12(p70) 64.0 ± 19.1c 17.1 ± 3.1
G-CSF 5157.0 ± 1095.0c 2208.0 ± 433.1
GM-CSF 198.6 ± 44.6b 22.6 ± 8.7
IFNα 30.3 ± 4.4d 0.7 ± 0.6
IFNβ 445.3 ± 93.2b 13.8 ± 3.5
IFNγ 76.8 ± 18.8c BDL(43.1)
MIP-1α 2770.7 ± 484.0b 440.0 ± 127.0
MIP-1β 4140.0 ± 570.5c 2232.0 ± 218.5
TNF-α 1109.6 ± 212.7b 232.6 ± 71.6
a The indicated cytokines were found to be induced by FSL-1 
application by BioPlex or ELISA as indicated in the methods. Data are 
presented as mean ± SEM of five replicates from two independent 
experiments.
b p < 0.01 compared to DPBS vehicle (Student's t-test).
c p < 0.05 compared to DPBS vehicle (Student's t-test).
d p < 0.001 compared to DPBS vehicle (Student's t-test).
e BDL; Below Detection Limit (for statistical comparisons with these 
cytokines the value for the lowest standard of each cytokine was 
utilized).Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
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with the mechanism of action for previously evaluated
anti-herpetic TLR agonists [14,15,17,19].
The FSL-1-induced increase in resistance to genital HSV-2
infection in mice is similar to the activity observed for
other anti-herpetic TLR agonists. Application of PIC, IMI
or CpG prior to viral challenge elicited significant resist-
ance to genital HSV-2 infection while PGN, LPS or FLAG
showed no activity [14,15,17,19]. The HSV-2 genome is
composed of double-stranded DNA that is recognized by
TLR9 [11,24,35]. Also, viral replication potentially pro-
duces double- or single-stranded RNA intermediates that
are recognized by TLR3 or TLR7/8, respectively
[11,24,36,37]. There are no published reports showing
HSV-2 recognition through TLR5 and recent data indi-
cated that PGN recognition occurs through NOD1/2 or
TLR2 [11,38,39]. Interpretation of the results would sug-
gest that induction of anti-herpetic activity is specific to
viral-associated agonists, but recent work by Ashkar et al.
showed that FimH, a TLR4 agonist derived from E. coli,
provided significant resistant to genital HSV-2 infection
while LPS from E. coli was ineffective [20]. Additionally,
we showed that FSL-1, a bacterial-derived diacyl lipopep-
tide [21,22], significantly increased resistance to HSV-2
infection in mouse and human models. The varying anti-
herpetic activity observed following activation of different
TLR pathways indicates that effective agonists likely
induce a specific innate immune response profile that
produces an HSV-2 resistant environment.
FSL-1 elaborated a cytokine response profile consistent
with other anti-herpetic TLR agonists. Vaginal application
of CpG in mice resulted in elaboration of IL-12, IL-18,
IFNγ and RANTES [15,16,19]. The cytokine profile elicited
by PIC or IMI vaginal treatment was similar to CpG and
included secretion of IL-1α, IL-1β, IL-6, IL-12, IFNβ, IFNγ,
MIP-1α and RANTES [15,17,19]. Interestingly, vaginal
delivery of PGN or FLAG in mice did not result in produc-
Figure 2
FSL-1 delivered once daily for 5 consecutive days did not  induce chronic inflammation Figure 2
FSL-1 delivered once daily for 5 consecutive days did 
not induce chronic inflammation. As a marker of an 
inflammatory state, IL-1α, IL-6 and TNF-α were kinetically 
quantified in murine lavages of repetitive daily dosed animals 
(n = 5/treatment). Each cytokine was induced significantly (*, 
p < 0.05; Student's t-test) 6 h after FSL-1 (6 μg; closed 
square) application compared to DPBS vehicle (60 μL; open 
circle). Notably, by 24 h after each FSL-1 dose, induced 
cytokines had returned to DPBS vehicle levels and were not 
significantly (p > 0.05; Student's t-test) increased 24 h after 
the final FSL-1 application. Each collection time point is pre-
sented as mean ± SEM of five replicates from two independ-
ent experiments.Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
Page 8 of 11
(page number not for citation purposes)
tion of IFNα or IFNβ [15]. Based on the observed cytokine
profile elicited by FSL-1 6 h post-application (Table 3)
and other in vitro or in vivo experiments [15-17,19,40-
45], a preliminary anti-herpetic cytokine profile would
include IL-2, IL-12(p40), IL-12(p70), IFNβ, IFNγ, MIP-1α,
MIP-1β and RANTES.
The identified cytokines are important for providing
resistance to genital HSV-2 infection through direct anti-
herpetic activity or through stimulation and activation of
leukocytes. Gill et al. and others showed that IFNβ pro-
duction correlated with protection of mice against experi-
mental genital HSV-2 infection [15,19]. Type I interferons
(IFNα, IFNβ) act by directly inhibiting HSV-2 replication
and skew the immune system towards a TH1-baised
response [42,44,46]. A TH1-associated immune response
is important for controlling early replication of HSV-2 and
for effective clearance of the infection [42,44,47]. Elabora-
tion of IL-2 and IL-12 also aids the innate immune
response against HSV-2 through stimulation and activa-
tion of leukocytes and induction of type II interferon
(IFNγ) [16,40,45]. Resistance to HSV-2 is enhanced by the
direct anti-herpetic activity of MIP-1α, MIP-1β and
RANTES [43]. The chemokines also are important for the
recruitment of leukocytes that aid in the regulation of the
anti-herpetic immune response [41,43].
Importantly, the TLR agonist-induced innate immune
response against HSV-2 infection must provide adequate
resistance without producing chronic inflammation that
Single or multiple FSL-1 dosing did not induce organ enlargement Figure 3
Single or multiple FSL-1 dosing did not induce organ enlargement. As an additional measure of peripheral immunoto-
xicity, immune cell migration was evaluated by gross observation of associated lymphoid tissues following FSL-1 application. 
GLN, liver and spleen weights for organs collected 2 or 5d after delivery of FSL-1 (6 μg; closed square) or DPBS vehicle (60 μL; 
open circle) in a single or 5 multiple once daily doses. By organ, the mean % of total body weight for each group is demarcated 
by the horizontal line with each point representing one mouse (n = 5/group). Weights of organs collected 2d after the last of 5 
consecutive daily FSL-1 doses were not significantly (p > 0.05; Student's t-test) different than organs collected from mice 
treated with an equivalent volume of the DPBS vehicle. Similar statistically (p > 0.05; Student's t-test) indistinguishable results 
were observed for organs collected 2 or 5d after a single FSL-1 dose (data not shown). Groups were compared for statistical 
significance by one-way ANOVA.Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
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can potentially increase acquisition of STI. Kinetic vaginal
cytokine elaboration and organ weights following FSL-1
application were evaluated and showed no chronic or sys-
temic outcomes. Chronic inflammation could result in
disruption of the vaginal mucosal barrier leading to
increased susceptibility to STI [30] so careful analyses of
prolonged inflammation are necessary. Our initial studies
indicated that even repeated dosing with FSL-1 did not
create a chronically inflamed vaginal tract (Figure 3). Also,
the treatment regimen resulted in no enlargement of the
GLN, spleen or liver (Figure 4). PIC application in mice
produced similar results but specific pro-inflammatory
cytokines remained elevated until 48 h post-application
[17]. Further, Ashkar et al. showed that delivery of CpG
resulted in significant enlargement of the spleen in mice
due to a large influx of immune cells [14]. The observed
systemic immunotoxicity following CpG application
highlights the need for a TLR agonist that not only pro-
vides resistance to genital HSV-2 infection but does not
negatively impact the vaginal mucosa or associated lym-
phoid tissues [30]. Comparison of the preliminary FSL-1
safety profile to other TLR agonists confirmed that the
mouse model is useful for assessing the preliminary safety
profile of immunomodulatory compounds prior to eval-
uation in expensive and lengthy clinical trials.
In summary, we showed that the TLR2/6 agonist FSL-1 is
capable of significantly increasing resistance to HSV-2
infection in mice through induction of a specific cytokine
response profile. The identified anti-herpetic profile is of
critical importance for the future design of TLR agonist
interventions and will aid in improving the efficacy of
promising adjuvants for HSV-2 vaccines [48,49]. Addi-
tionally, the vaginal EC-elicited innate immune response
following FSL-1 application provides intriguing rationale
for investigation into the impact of secondary reproduc-
tive tract infections by genital mycoplasmas or other
potential coinfecting pathogens on HSV-2 transmission.
Indeed, HSV-2 is associated with increased susceptibility
to other important bacterial and viral STI including HIV-1
[1,5-7]. Continued investigation into the innate response
to specific TLR agonists like FSL-1 will provide a greater
understanding of how pathogens are recognized in the
polymicrobial environment of the vagina and how these
responses can be exploited to develop novel strategies for
STI prevention.
FSL-1 significantly reduced HSV-2 replication in vitro Figure 4
FSL-1 significantly reduced HSV-2 replication in vitro. Triplicate human vaginal EC cultures were treated with FSL-1 (6 
μg or 0.1 μg) at 24 h (black bar), 6 h (grey bar) or just prior (white bar) to HSV-2 inoculation (104pfu/well). A separate set of 
cultures were treated with the DPBS vehicle, infected and processed in parallel (hatched bar). Following 24 h of viral infection, 
each well was collected (100 μL) and 50 μL of the sample was used for standard plaque titration assays. DNA was extracted 
from the remaining sample (50 μL) and subjected to quantitative PCR to measure the amount of viral replication. FSL-1 (6 μg) 
delivered 24 or 6 h prior to infection significantly (*, p < 0.05; student's t-test) reduced viral replication compared to the DPBS 
vehicle for both PCR and plaque titration analyses. For the 0.1 μg FSL-1 dose, significant (*, p < 0.05; student's t-test) reduction 
in GE was observed 24 h prior to HSV-2 inoculation while significant (*, p < 0.05; student's t-test) reduction in pfu was 
observed 6 h prior to viral challenge. Addition of FSL-1 at either dose just prior to infection did not impact HSV-2 replication. 
Results are presented as the mean ± SEM from two separate experiments using three vaginal EC lines (V11I, V12I, V19I) in 
each experiment.Virology Journal 2009, 6:195 http://www.virologyj.com/content/6/1/195
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Conclusion
￿ The bacteria-derived FSL-1 TLR2/6 agonist applied
vaginally to mice increased resistance to HSV-2 chal-
lenge.
￿ The observed FSL-1 anti-herpetic resistance may
indicate that pre-existing colonization by Mycoplasma
spp or other bacteria, including commensals, that pro-
duce diacyl lipopeptides could alter HSV-2 susceptibil-
ity.
￿ Application of FSL-1 to human vaginal epithelial
cells reduced HSV-2 replication.
￿ Based on the cytokines produced by FSL-1, PIC and
CpG TLR agonists it appears that IL-2, IL-12(p40), IL-
12(p70), IFNβ, IFNγ, MIP-1α, MIP-1β and RANTES
contribute to resistance to HSV-2.
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